DK0446570T3 - Gabapentin og dets derivater til behandling af neurodegenerative sygdomme - Google Patents

Gabapentin og dets derivater til behandling af neurodegenerative sygdomme

Info

Publication number
DK0446570T3
DK0446570T3 DK91100109.7T DK91100109T DK0446570T3 DK 0446570 T3 DK0446570 T3 DK 0446570T3 DK 91100109 T DK91100109 T DK 91100109T DK 0446570 T3 DK0446570 T3 DK 0446570T3
Authority
DK
Denmark
Prior art keywords
gabapentin
derivatives
treatment
neurodegenerative diseases
huntington
Prior art date
Application number
DK91100109.7T
Other languages
English (en)
Inventor
Geoffrey Neil Woodruff
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27039510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0446570(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DK0446570T3 publication Critical patent/DK0446570T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK91100109.7T 1990-01-02 1991-01-02 Gabapentin og dets derivater til behandling af neurodegenerative sygdomme DK0446570T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45991290A 1990-01-02 1990-01-02
US07/615,151 US5084479A (en) 1990-01-02 1990-11-23 Novel methods for treating neurodegenerative diseases

Publications (1)

Publication Number Publication Date
DK0446570T3 true DK0446570T3 (da) 1995-11-27

Family

ID=27039510

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91100109.7T DK0446570T3 (da) 1990-01-02 1991-01-02 Gabapentin og dets derivater til behandling af neurodegenerative sygdomme

Country Status (7)

Country Link
US (1) US5084479A (da)
EP (1) EP0446570B1 (da)
JP (1) JP2903434B2 (da)
AT (1) ATE125701T1 (da)
DE (1) DE69111642T2 (da)
DK (1) DK0446570T3 (da)
HK (1) HK1005166A1 (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5217957A (en) * 1991-08-20 1993-06-08 Warner-Lambert Company Cholecystokinin antagonists useful for treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
CZ293759B6 (cs) * 1996-03-14 2004-07-14 Warner-Lambert Company Substituovaná cyklická aminokyselina, její použití a farmaceutický prostředek na její bázi
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
UA61962C2 (uk) * 1997-06-30 2003-12-15 Мерц Фарма Гмбх Унд Ко. Кгаа Сполука 1-аміноалкілциклогексану, фармацевтична композиція на її основі та спосіб лікування
US6194459B1 (en) 1997-08-19 2001-02-27 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotors stimulants
WO1999018063A2 (en) 1997-10-07 1999-04-15 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
KR100589066B1 (ko) 1997-10-27 2006-06-13 워너-램버트 캄파니 엘엘씨 약제로서 유용한 시클릭 아미노산 및 그의 유도체
DE19751062A1 (de) 1997-11-18 1999-07-08 Univ Ludwigs Albert An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels
US6984659B2 (en) 1997-11-18 2006-01-10 Klinikum Der Albert-Ludwigs Universitaet 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
PL205145B1 (pl) * 1998-05-15 2010-03-31 Warner Lambert Co Trwała kompozycja stała zawierająca pochodną 4-amino-3-podstawionego kwasu butanowego oraz sposób jej wytwarzania
IL139298A0 (en) 1998-05-15 2001-11-25 Warner Lambert Co Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
US6294198B1 (en) 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
US6350768B1 (en) 1999-11-24 2002-02-26 Aventis Pharma S.A. Combination of riluzole and of gabapentin and its use as a medicament
FR2801217B1 (fr) * 1999-11-24 2002-12-06 Aventis Pharma Sa Association de riluzole et de gabapentine et son utilisation comme medicament
EP1289364B1 (en) 2000-06-16 2003-12-10 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 2o ppm of chlorine ion
AU2001266992B8 (en) * 2000-06-16 2005-12-01 Teva Pharmaceutical Industries Ltd. Stable gabapentin having pH within a controlled range
ATE390133T1 (de) * 2000-06-26 2008-04-15 Warner Lambert Co Gabapentinanaloga für schlafstörungen
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
MXPA03011566A (es) * 2001-06-11 2004-10-28 Xenoport Inc Formas de dosificacion de profarmacos de analogos de gaba administrados oralmente que tienen toxicidad reducida.
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7420002B2 (en) * 2001-06-11 2008-09-02 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
ITMI20012750A1 (it) 2001-12-21 2003-06-21 Procos Spa Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
US6927036B2 (en) * 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
EP1494996A1 (en) * 2002-04-16 2005-01-12 Taro Pharmaceutical Industries Limited Process for preparing gabapentin
AU2003243180A1 (en) * 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
AU2003297909A1 (en) * 2002-12-11 2004-06-30 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
US7060727B2 (en) 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
WO2005027850A2 (en) 2003-09-17 2005-03-31 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
MXPA06004088A (es) 2003-10-14 2006-06-27 Xenoport Inc Forma cristalina de un analogo del acido gamma-aminobutirico.
CA2553291A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. Combination of .gamma.-aminobutyric acid modulators and 5-ht1b receptor antagonists
US20050187295A1 (en) * 2004-02-19 2005-08-25 Surendra Kalyan Processes for the preparation of gabapentin
ITMI20040579A1 (it) * 2004-03-25 2004-06-25 Zambon Spa Processo di preparazione di gabapentina
EP1811986B1 (en) 2004-11-04 2014-03-26 XenoPort, Inc. Gabapentin prodrug sustained release oral dosage forms
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20130078290A1 (en) 2010-06-01 2013-03-28 Rubicon Research Private Limited Gastroretentive Dosage Forms Of GABA Analogs
WO2015144825A1 (en) 2014-03-27 2015-10-01 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
AU2020370758B2 (en) * 2019-10-25 2025-08-14 Kyoto University Preventative or therapeutic agent for tauopathy
CN115350172A (zh) * 2022-08-12 2022-11-18 昆明医科大学 Gabapentin对AD情景记忆改善的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Also Published As

Publication number Publication date
JPH04210915A (ja) 1992-08-03
EP0446570A2 (en) 1991-09-18
EP0446570B1 (en) 1995-08-02
US5084479A (en) 1992-01-28
DE69111642D1 (de) 1995-09-07
DE69111642T2 (de) 1996-01-25
JP2903434B2 (ja) 1999-06-07
EP0446570A3 (en) 1992-04-01
ATE125701T1 (de) 1995-08-15
HK1005166A1 (en) 1998-12-24

Similar Documents

Publication Publication Date Title
EP0446570A3 (en) Gabapentin and its derivatives for treating neurodegenerative diseases
DK0414275T3 (da) Fremgangsmåde til fremtilling af cycliske aminosyrederivater samt mellemprodukter
DK0831799T3 (da) Forbindelser, der er aktive ved et nyt sted på receptor-stimulerede calsiumkanaler, og som kan anvendes til behandling af neurologiske sygdomme
EP1404324A4 (en) PROGRUGS OF GABA ANALOGUE, COMPOSITIONS AND ITS USES
SE8704204L (sv) Substituerade alfa-aminosyror, deras framstellning och farmaceutiska kompositioner innehallande desamma
ATE246188T1 (de) Substituierte sulfonylphenylheterocyclen als cyclooxygenase-2 und lipoxygenase inhibitoren
DE60124080D1 (de) Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
BR9812837A (pt) Processo para fazer um composto, e, composto
DE60237635D1 (de) Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose
DE69716810D1 (de) 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
ES2116298T3 (es) Nuevo metodo de tratamiento de la depresion.
DE69014707D1 (de) Verfahren zur Herstellung von CMOS-Feldeffekt-Transistoren.
ATE526981T1 (de) Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DK671187D0 (da) Anvendelse af 5-aryl-3h-1,2,4-triazol-3-oner ved behandling af neurodegenerative sygdomme
ES2100023T3 (es) Nuevos derivados 17,20-epoxidos del pregnano, su aplicacion a la preparacion de derivados cortisonicos y productos intermedios.
FI97884B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 3,4-dihydroksi-2,5-dihydrofuranonien valmistamiseksi
FI102537B (fi) Dehalogenointimenetelmä 3-aroyyli-2-oksindoli-1-karboksiamidien valmis tamiseksi
DE69930880D1 (de) Bicyclische(3.1.0)hexane und verwandte Verbindungen
ATE137973T1 (de) Phospholipide zur behandlung der multiplen sklerose